Development of a new test for the global fibrinolytic capacity in whole blood

摘要: Background: The development of global tests for the fibrinolytic capacity in blood is hampered by low base-line activity blood, involvement both plasmatic components and cells system loss as a result action plasminogen activator inhibitor-1 (PAI-1). Objective: To develop new test (GFC) whole samples. Methods results: Collection thrombin increased subsequent generation fibrin degradation products. This was ascribed to rapid clot formation concomitant reduction vitro neutralization tissue-type (tPA) PAI-1. On basis this observation, following designed: samples were collected with without aprotinin clots incubated 3h at 37°C. GFC assessed from difference between products two sera. assay applied patients healthy subjects. Other hemostasis parameters determined plasma taken simultaneously. varied considerably (normal range 0.13-13.6 μg mL-1); physical exercise strongly GFC. Statistically significant correlations found tPA activity, PAI-1 fibrinogen level. A mixture antibodies against urokinase-type (uPA) completely inhibited An inhibitor activated thrombin-activatable fibrinolysis (TAFI) accelerated 8-fold. Conclusion: represents assessment main factors potentially those associated cells. © 2007 International Society on Thrombosis Haemostasis.